| Literature DB >> 21629653 |
Jutta Sharbati1, Astrid Lewin, Barbara Kutz-Lohroff, Elisabeth Kamal, Ralf Einspanier, Soroush Sharbati.
Abstract
BACKGROUND: Many efforts have been made to understand basal mechanisms of mycobacterial infections. Macrophages are the first line of host immune defence to encounter and eradicate mycobacteria. Pathogenic species have evolved different mechanisms to evade host response, e.g. by influencing macrophage apoptotic pathways. However, the underlying molecular regulation is not fully understood. A new layer of eukaryotic regulation of gene expression is constituted by microRNAs. Therefore, we present a comprehensive study for identification of these key regulators and their targets in the context of host macrophage response to mycobacterial infections. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2011 PMID: 21629653 PMCID: PMC3101234 DOI: 10.1371/journal.pone.0020258
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Heatmaps of mRNA expression data of MAH infected MDMs after microarray analysis.
Columns represent temporal expression of MDMs at 6, 24 and 48 h p.i. with MAH strains 10091/06 and 104. Colours represent log 2 ratios of the infected cells versus the non-infected control according to the scales shown below. Samples represent a pool of three independent infection experiments. Panel A shows 36 genes possessing 2- to 39-fold (median of all time points) increased expression upon infection, while 10 genes were 2- to 3-fold down-regulated. Panel B and C illustrate mRNAs being temporally induced or repressed after infection. Panel D reflects dysregulated miRNAs after infection, while panel E shows temporally induced miRNAs. An averaged trace of the expression profile is integrated as a white graph by the acuity software (Panel B, C and E). Underlined mRNAs and miRNAs are addressed in the results section.
Differentially expressed protein coding genes after MAH infection.
| Gene Symbol | Gene Desciption | Log 2 Ratio |
| INHBA | inhibin, beta A | 5.3 |
| CCL1 | chemokine (C-C motif) ligand 1 | 5.1 |
| IL1B | interleukin 1, beta | 4.5 |
| VEGFC | vascular endothelial growth factor C | 4.0 |
| MMP3 | matrix metallopeptidase 3 (stromelysin 1, progelatinase) | 3.7 |
| SLAMF1 | signaling lymphocytic activation molecule family member 1 | 3.6 |
| CCR7 | chemokine (C-C motif) receptor 7 | 3.3 |
| MMP1 | matrix metallopeptidase 1 (interstitial collagenase) | 3.3 |
| TNFAIP6 | tumor necrosis factor, alpha-induced protein 6 | 3.3 |
| TNIP3 | ABIN-3, LIND; TNFAIP3 interacting protein 3 | 3.2 |
| CCL20 | chemokine (C-C motif) ligand 20; K05514 C-C motif chemokine, other | 3.2 |
| IL7R | interleukin 7 receptor; K05072 interleukin 7 receptor | 3.0 |
| PROCR | protein C receptor, endothelial; K06557 protein C receptor, endothelial (EPCR) | 3.0 |
| PDGFB | platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog) | 2.9 |
| CSF2 | colony stimulating factor 2 (granulocyte-macrophage) | 2.8 |
| TNF | tumor necrosis factor | 2.8 |
| CCL3-CCL3L1-CCL3L3 | chemokine (C-C motif) ligand 3 - chemokine (C-C motif) ligand 3-like 1 - chemokine (C-C motif) ligand 3-like 3 | 2.5 |
| IL8 | interleukin 8; K10030 interleukin 8 | 2.4 |
| IL3RA | IL3RA, CD123, IL3R, IL3RAY, IL3RX, IL3RY, MGC34174, hIL-3Ra; interleukin 3 receptor, alpha (low affinity | 2.4 |
| BMP6 | BMP6, VGR, VGR1; bone morphogenetic protein 6; K04663 bone morphogenetic protein 5/6/7/8 | 2.4 |
| MSC | musculin (activated B-cell factor-1) | 2.3 |
| CCL4-CCL4L2-CCL4L1 | chemokine (C-C motif) ligand 4 - chemokine (C-C motif) ligand 4-like 2 - chemokine (C-C motif) ligand 4-like 1 | 2.3 |
| TM4SF1 | transmembrane 4 L six family member 1 | 2.3 |
| TNFRSF9 | tumor necrosis factor receptor superfamily, member 9 | 2.3 |
| MRC1 | mannose receptor, C type 1 | 2.3 |
| LAMB3 | laminin, beta 3; K06244 laminin, beta 3 | 2.2 |
| TNFRSF19 | tumor necrosis factor receptor superfamily, member 19 | 2.2 |
| CCL5 | RANTES, chemokine (C-C motif) ligand 5 | 2.1 |
| CHST2 | GST2, carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 | 2.0 |
| ETS2 | v-ets erythroblastosis virus E26 oncogene homolog 2 (avian | 2.0 |
| TNFSF9 | CD137L; tumor necrosis factor (ligand) superfamily, member 9 | 2.0 |
| CCL18 | AMAC1, MIP-4, chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) | 2.0 |
| PTGS2 | COX2, prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | 1.9 |
| IL10 | interleukin 10 | 1.9 |
| SOCS3 | suppressor of cytokine signaling 3 | 1.9 |
| SERPINB2 | serpin peptidase inhibitor, clade B (ovalbumin) | 1.8 |
| SERPINE1 | PAI, serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 | 1.8 |
| TIMP1 | metallopeptidase inhibitor 1 | 1.8 |
| BTG1 | B-cell translocation gene 1, anti-proliferative | 1.8 |
| SOD2 | superoxide dismutase 2, mitochondrial | 1.8 |
| CD14 | CD14 molecule | 1.7 |
| MMP10 | matrix metallopeptidase 10 (stromelysin 2) | 1.5 |
| PLAUR | plasminogen activator, urokinase receptor | 1.5 |
| NFKBIA | nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | 1.4 |
| CD40 | TNFRSF5, CD40 molecule, TNF receptor superfamily member 5 | 1.3 |
| MMP14 | matrix metallopeptidase 14 (membrane-inserted) | 1.3 |
| IRF1 | interferon regulatory factor 1 | 1.3 |
| BIRC3 | AIP, baculoviral IAP repeat-containing 3 | 1.2 |
| ICAM1 | CD54, intercellular adhesion molecule 1 | 1.2 |
| CD44 | CD44 molecule | 1.1 |
| CDKN1B | cyclin-dependent kinase inhibitor 1B (p27, Kip1) | 1.1 |
| BATF | basic leucine zipper transcription factor, ATF-like; K09034 ATF-like basic leucine zipper transcriptional factor | 1.1 |
| CSF2RA | GMCSFR, colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) | 1.1 |
| FCGR2A-FCGR2B-FCGR2C | Fc fragment of IgG, low affinity IIa, receptor (CD32) - Fc fragment of IgG, low affinity IIb, receptor (CD32) - Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene) | 1.1 |
| CD82 | KAI1, CD82 molecule, kangai 1 | 1.0 |
| ITGA5 | CD49e, integrin, alpha 5 (fibronectin receptor, alpha polypeptide) | 1.0 |
| CXCL10 | chemokine (C-X-C motif) ligand 10 | 1.0 |
| QSOX1 | quiescin Q6 sulfhydryl oxidase 1 | 1.0 |
| PIAS1 | protein inhibitor of activated STAT, 1 | −1.0 |
| PRKCB | protein kinase C, beta | −1.0 |
| SMAD2 | MADH2, SMAD family member 2, mothers against DPP 2/3 | −1.0 |
| PARP1 | poly (ADP-ribose) polymerase 1 | −1.0 |
| CD9 | MIC3, CD9 molecule | −1.0 |
| IL18BP | interleukin 18 binding protein | −1.1 |
| NFATC3 | nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 | −1.1 |
| CD52 | CD52 molecule | −1.1 |
| LGALS3 | GALBP, lectin, galactoside-binding, soluble, 3 | −1.1 |
| CCNE1 | cyclin E1 | −1.2 |
| STMN1 | stathmin 1 | −1.6 |
| LTA4H | leukotriene A4 hydrolase | −1.7 |
| CD36 | CD36 molecule | −1.7 |
*Binary log ratio of increased or decreased gene expression according to microarray analysis of MAH infected macrophages compared to non-infected controls. At least 2-fold (corresponding to Log 2 ratios of ≥1 or ≤−1) altered expression of median of values for 6, 24 and 48 h, as well as MAH 10091/06 and MAH 104 was considered.
Distribution of differentially expressed genes among biochemical pathways.
| Functionally enriched Pathways | % of Genes | Associated Genes |
| Fc Epsilon Receptor I Signaling in Mast Cells | 20 | BTK, JUN, LYN, MAPK3, PRKCB, SYK |
|
| 12 | BTK, CSF2, LYN, MAP2K3, MAPK3, PLCG2, PRKCB, SYK, TNF |
| Complement and coagulation cascades | 9 | C1QA, C3AR1, CD46, PLAU, PLAUR, SERPINE1 |
|
| 19 | CD14, JUN, MAP2K3, MYD88, NFKB1, NFKBIA, TLR2 |
|
| 16 | CCL5, CD14, CD40, CXCL10, IL1B, IL8, JUN, MAP2K3, MAP3K8, MAPK3, MYD88, NFKB1, NFKBIA, STAT1, TLR2, TNF |
|
| 14 | BID, BIRC3, CASP3, CASP6, CFLAR, FAS, IL1B, IL3RA, MYD88, NFKB1, NFKBIA, TNF |
| Apoptotic Signaling in Response to DNA Damage | 24 | BID, CASP3, CASP6, PARP1, STAT1 |
|
| 17 | BIRC3, CASP3, CASP6, PARP1 |
| FAS signaling pathway (CD95) | 20 | CASP3, CASP6, CFLAR, FAS, JUN, PARP1 |
| p53 signaling pathway | 10 | BID, CASP3, CCNE1, CD82, CDKN1A, FAS, SERPINE1 |
| ATM Signaling Pathway | 21 | BRCA1, JUN, NFKB1, NFKBIA |
| Free Radical Induced Apoptosis | 44 | IL8, NFKB1, SOD1, TNF |
|
| 21 | BID, CASP3, CASP6, CFLAR, NFKB1, NFKBIA |
| Influence of Ras and Rho proteins on G1 to S Transition | 25 | CCNE1, CDKN1B, MAPK3, NFKB1, NFKBIA, RHOA |
| Role of Mitochondria in Apoptotic Signaling | 19 | BID, BIRC3, CASP3, CASP6 |
|
| 18 | MYD88, NFKB1, NFKBIA, TNF |
| NFkB activation by Nontypeable Hemophilus influenzae | 33 | IL1B, IL8, MAP2K3, MYD88, NFKB1, NFKBIA, TLR2, TNF |
|
| 11 | CCL1, CCL18, CCL20, CCL22, CCL5, CCR1, CCR5, CCR7, CD40, CSF2, CSF2RA, CXCL10, FAS, IFNGR1, IL10, IL1B, IL3RA, IL7R, IL8, INHBA, PDGFB, TNF, TNFRSF19, TNFRSF9, TNFSF13, TNFSF13B, TNFSF9, VEGFB, VEGFC |
|
| 15 | CSF2, IL10, IL8, TNF |
| Dendritic cells in regulating TH1 and TH2 Development | 19 | CD40, CSF2, IL10, TLR2 |
| IL-2 Receptor Beta Chain in T cell Activation | 15 | CFLAR, FAS, MAPK3, SOCS3, SYK |
| T cell receptor signaling pathway | 10 | CSF2, IL10, JUN, MAP3K8, NFATC3, NFKB1, NFKBIA, RHOA, TNF |
| Cadmium induces DNA synthesis and proliferation in macrophages | 36 | JUN, MAPK3, NFKB1, NFKBIA, TNF |
| Selective expression of chemokine receptors during T-cell polarization | 19 | CCR1, CCR5, CCR7, CSF2, IFNGR1 |
| B cell receptor signaling pathway | 14 | BTK, JUN, LYN, NFATC3, NFKB1, NFKBIA, PLCG2, PRKCB, SYK |
| Natural killer cell mediated cytotoxicity | 9 | BID, CASP3, CSF2, FAS, ICAM1, IFNGR1, MAPK3, NFATC3, PLCG2, PRKCB, SYK, TNF |
| fMLP induced chemokine gene expression in HMC-1 cells | 16 | MAP2K3, MAPK3, NFKB1, NFKBIA |
| TNF/Stress Related Signaling | 21 | JUN, MAP2K3, NFKB1, NFKBIA, TNF |
| TNFR1 Signaling Pathway | 14 | CASP3, JUN, PARP1, TNF |
| The 4-1BB-dependent immune response | 29 | JUN, NFKB1, NFKBIA, TNFRSF9, TNFSF9 |
| Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha) | 12 | HSP90AA1, JUN, MAPK3, NFKBIA, TNF |
| Signal transduction through IL1R | 24 | IL1B, JUN, MAP2K3, MYD88, NFKB1, NFKBIA, TNF |
| MAPKinase Signaling Pathway | 10 | JUN, MAP2K3, MAP3K8, MAPK3, MAPK6, NFKB1, NFKBIA, STAT1 |
| ECM-receptor interaction | 9 | CD36, CD44, CD47, ITGA5, ITGA6, ITGB3, ITGB5, LAMB3 |
| Epithelial cell signaling in Helicobacter pylori infection | 12 | CASP3, CCL5, IL8, JUN, LYN, NFKB1, NFKBIA, PLCG2 |
| Hematopoietic cell lineage | 17 | CD14, CD36, CD44, CD9, CSF2, CSF2RA, FCGR1A, IL1B, IL3RA, IL7R, ITGA5, ITGA6, ITGB3, MME, TNF |
| Chaperones modulate interferon Signaling Pathway | 24 | IFNGR1, NFKB1, NFKBIA, TNF |
| Alzheimer's disease | 18 | C1QA, CASP3, IL1B, MME, TNF |
*Pathways containing at least 4 differentially expressed genes (or 8%). Underlined pathways are referred to in the results section.
**Percentage of the differentially expressed genes which share a pathway membership with regard to all pathway-associated genes according to Reactome/Biocarta and Kegg pathway databases implemented in Cytoscape 2.7.0.
***Differentially expressed genes with shared pathway memberships. Differentially expressed genes with at least 1.5-fold altered expression compared to non-infected control cells and having valid expression signals in at least 4 out of 6 microarray experiments were considered for pathway mapping. Genes showing temporal expression pattern, as depicted in figure 1 B and C, were also included in the analysis.
Figure 2Regulatory network of MAH infected MDMs deduced from integrated analysis of miRNA-mRNA microarray data.
Negatively correlated miRNA-mRNA interactions were visualised as a network using Cytoscape. This network gives for the first time an theoretical outline of the concerted action of regulating miRNAs (blue triangles) and their potential target mRNAs (green circles) in mycobacterial infection of human macrophages.
Functional enrichment of pathways deduced from integrated miRNA-mRNA analysis.
| Functionally enriched Pathways | Potential Target Genes | Potential miRNA regulators | % of Genes |
| Cytokines and Inflammatory Response | IL10, IL8 | hsa-let-7e, hsa-let-7f, hsa-let-7g, hsa-let-7i, hsa-mir-27a, hsa-mir-374a, hsa-let-7a, hsa-mir-20a | 8 |
| NFkB activation by Nontypeable Hemophilus influenzae | IL8, MAP2K3 | hsa-let-7i, hsa-mir-20a, hsa-let-7a, hsa-let-7ghsa-let-7f, hsa-let-7e, hsa-mir-21 | 8 |
| Caspase Cascade in Apoptosis | CASP3, CASP6 | hsa-let-7i, hsa-let-7e, hsa-let-7f, hsa-let-7g, hsa-let-7a, hsa-mir-30b, hsa-mir-30c, hsa-mir-185 | 9 |
| Induction of apoptosis through DR3 and DR4/5 Death Receptors | BID, CASP3, CASP6 | hsa-mir-26b, hsa-mir-26a, hsa-let-7i, hsa-let-7e, hsa-let-7f, hsa-let-7g, hsa-let-7a, hsa-mir-30b, hsa-mir-30c, hsa-mir-185 | 11 |
| FAS signaling pathway ( CD95 ) | CASP3, CASP6 | hsa-let-7i, hsa-let-7e, hsa-let-7f, hsa-let-7g, hsa-let-7a, hsa-mir-30b, hsa-mir-30c, hsa-mir-185 | 7 |
| TSP-1 Induced Apoptosis in Microvascular Endothelial Cell | CASP3, CD36 | hsa-let-7i, hsa-let-7e, hsa-let-7f, hsa-let-7g, hsa-let-7a, hsa-mir-30b, hsa-mir-30c, hsa-mir-423-5p | 29 |
| Fc Epsilon Receptor I Signaling in Mast Cells | PRKCB, SYK | hsa-mir-185, hsa-mir-886-5p | 7 |
| Selective expression of chemokine receptors during T-cell polarization | CCR1, CCR7 | hsa-mir-185, hsa-mir-423-5p, hsa-let-7g, hsa-mir-21, hsa-let-7f, hsa-let-7i, hsa-let-7e, hsa-let-7a, hsa-mir-423-5p | 8 |
*Pathways containing at least 2 differentially expressed genes (or 4%).
**Predicted Target genes showing negatively correlated expression compared with miRNA expression data. Differentially expressed genes with at least 2-fold altered or temporal expression and regarding expression data of each time point and MAH strain were considered (listed in figure A–C).
***miRNAs predicted to target differentially expressed genes with negatively correlated expression data. Each miRNA is predicted to target at least one of the listed genes in column 2.
****Percentage of the differentially expressed genes which share a pathway membership with regard to all associated genes according to Reactome/Biocarta and Kegg pathway databases implemented in Cytoscape 2.7.0.
Figure 3Temporal CASP3/CASP7 activity upon MAH infection of MDMs.
MDMs were infected with bacteria and the luminescence signal (relative light units, RLU) proportional to the activity of CASP3/CASP7 was measured. Columns represent the mean of quintuplicate measurements while error bars show the standard deviation. Asterisks indicate statistical significance according to paired t test (***: P<0.001).
Figure 4mRNA expression data of MAH infected MDMs after qRT-PCR analysis.
Columns in panel A represent the individual expression of MDMs from three different human donors (Donor 1–3) infected with MAH strains 2514, 10091/06 and 104 as well as E. coli K12 as a control. Colours represent log 2 ratios of the means of triplicate measurements of infected cells versus the non-infected control according to the scales shown below. The box plots in panel B include the data obtained from all three infection experiments considering all three MAH strains. Log 2 ratios below −0.585 and above 0.585 (corresponding to 1.5-fold change) are indicated by the green and red dashed lines and were considered to reflect differential expression.
Figure 5miRNA expression data of MAH infected MDMs after miRNA specific qRT-PCR analysis.
The columns show the mean expression of distinct miRNAs from all three donors each measured in triplicates while error bars show the standard deviation. The calculated log 2 ratios of means of all donors relating to each MAH strain and E. coli K12 are shown, respectively. Asterisks indicate statistical significance according to unpaired t test (*: P<0.05; **: P<0.01; ***: P<0.001).
Figure 6Regulatory network of MAH infected MDMs deduced from integrated analysis of miRNA-mRNA expression after qRT-PCR experiments.
Negatively correlated miRNA-mRNA interactions were visualised as a network using Cytoscape. Lines represent predicted interactions considering negatively correlating miRNA (blue triangles) and mRNA (green circles) expression data.
Figure 7let-7e and miR-29a target CASP3 and CASP7, respectively.
Down-regulation of CASP3 and CASP7 by let-7e and miR-29a was verified using reporter gene assays. Panel A: Identified target sites between miRNAs and both caspases were analysed using RNAhybrid. Panel B: HeLa cells were co-transfected with miRNA mimics and plasmids harbouring the 3′ UTR of CASP3 and 7, respectively. Relative luciferase activity (Luc : Luc ) was determined respective to the a non-sense miRNA mimics serving as a control. The columns show means of normalised luciferase activity each measured in triplicates while error bars show the standard deviation. Asterisks indicate statistical significance between miRNA treated samples and non-sense miRNA treated controls according to paired t test (**: P<0.01).